nodes	percent_of_prediction	percent_of_DWPC	metapath
Pralatrexate—TYMS—Fluorouracil—skin cancer	0.645	1	CbGbCtD
Pralatrexate—FPGS—Fluoropyrimidine Activity—XRCC3—skin cancer	0.0103	0.188	CbGpPWpGaD
Pralatrexate—Neoplasm malignant—Vismodegib—skin cancer	0.00801	0.0403	CcSEcCtD
Pralatrexate—FPGS—nipple—skin cancer	0.00769	0.0815	CbGeAlD
Pralatrexate—SLC19A1—lymphoid tissue—skin cancer	0.00599	0.0634	CbGeAlD
Pralatrexate—SLC19A1—female reproductive system—skin cancer	0.00578	0.0612	CbGeAlD
Pralatrexate—FPGS—connective tissue—skin cancer	0.00546	0.0578	CbGeAlD
Pralatrexate—Pharyngolaryngeal pain—Imiquimod—skin cancer	0.00534	0.0269	CcSEcCtD
Pralatrexate—Laryngeal pain—Imiquimod—skin cancer	0.00529	0.0266	CcSEcCtD
Pralatrexate—DHFR—nipple—skin cancer	0.005	0.0529	CbGeAlD
Pralatrexate—Pain in extremity—Vismodegib—skin cancer	0.00496	0.025	CcSEcCtD
Pralatrexate—Neoplasm malignant—Vemurafenib—skin cancer	0.00495	0.0249	CcSEcCtD
Pralatrexate—FPGS—skin of body—skin cancer	0.00493	0.0522	CbGeAlD
Pralatrexate—SLC19A1—head—skin cancer	0.00482	0.0511	CbGeAlD
Pralatrexate—Dehydration—Vismodegib—skin cancer	0.00462	0.0233	CcSEcCtD
Pralatrexate—Hypokalaemia—Vismodegib—skin cancer	0.00452	0.0228	CcSEcCtD
Pralatrexate—FPGS—mammalian vulva—skin cancer	0.00449	0.0476	CbGeAlD
Pralatrexate—TYMS—Sorafenib—Vismodegib—skin cancer	0.00447	0.584	CbGdCrCtD
Pralatrexate—DHFR—Fluoropyrimidine Activity—XRCC3—skin cancer	0.00431	0.0787	CbGpPWpGaD
Pralatrexate—FPGS—lymphoid tissue—skin cancer	0.00399	0.0423	CbGeAlD
Pralatrexate—FPGS—female reproductive system—skin cancer	0.00385	0.0408	CbGeAlD
Pralatrexate—TYMS—Fluoropyrimidine Activity—XRCC3—skin cancer	0.00376	0.0687	CbGpPWpGaD
Pralatrexate—FPGS—Fluoropyrimidine Activity—ERCC2—skin cancer	0.00363	0.0663	CbGpPWpGaD
Pralatrexate—TYMS—connective tissue—skin cancer	0.00358	0.0379	CbGeAlD
Pralatrexate—DHFR—connective tissue—skin cancer	0.00354	0.0375	CbGeAlD
Pralatrexate—SLC19A1—lymph node—skin cancer	0.00338	0.0358	CbGeAlD
Pralatrexate—TYMS—skin of body—skin cancer	0.00323	0.0342	CbGeAlD
Pralatrexate—FPGS—head—skin cancer	0.00321	0.034	CbGeAlD
Pralatrexate—TYMS—Paclitaxel—Docetaxel—skin cancer	0.00319	0.416	CbGdCrCtD
Pralatrexate—Pain in extremity—Vemurafenib—skin cancer	0.00307	0.0155	CcSEcCtD
Pralatrexate—TYMS—mammalian vulva—skin cancer	0.00295	0.0312	CbGeAlD
Pralatrexate—DHFR—mammalian vulva—skin cancer	0.00292	0.0309	CbGeAlD
Pralatrexate—Back pain—Vismodegib—skin cancer	0.00289	0.0146	CcSEcCtD
Pralatrexate—Toxic epidermal necrolysis—Vemurafenib—skin cancer	0.00276	0.0139	CcSEcCtD
Pralatrexate—TYMS—lymphoid tissue—skin cancer	0.00262	0.0277	CbGeAlD
Pralatrexate—Pain in extremity—Imiquimod—skin cancer	0.00262	0.0132	CcSEcCtD
Pralatrexate—DHFR—lymphoid tissue—skin cancer	0.00259	0.0274	CbGeAlD
Pralatrexate—TYMS—female reproductive system—skin cancer	0.00252	0.0267	CbGeAlD
Pralatrexate—DHFR—female reproductive system—skin cancer	0.0025	0.0265	CbGeAlD
Pralatrexate—FPGS—lymph node—skin cancer	0.00225	0.0238	CbGeAlD
Pralatrexate—Pancytopenia—Imiquimod—skin cancer	0.00215	0.0108	CcSEcCtD
Pralatrexate—Pharyngolaryngeal pain—Docetaxel—skin cancer	0.00213	0.0107	CcSEcCtD
Pralatrexate—Decreased appetite—Vismodegib—skin cancer	0.00212	0.0107	CcSEcCtD
Pralatrexate—TYMS—head—skin cancer	0.00211	0.0223	CbGeAlD
Pralatrexate—Laryngeal pain—Docetaxel—skin cancer	0.00211	0.0106	CcSEcCtD
Pralatrexate—Fatigue—Vismodegib—skin cancer	0.0021	0.0106	CcSEcCtD
Pralatrexate—Upper respiratory tract infection—Imiquimod—skin cancer	0.0021	0.0106	CcSEcCtD
Pralatrexate—DHFR—head—skin cancer	0.00209	0.0221	CbGeAlD
Pralatrexate—Constipation—Vismodegib—skin cancer	0.00209	0.0105	CcSEcCtD
Pralatrexate—Sepsis—Dactinomycin—skin cancer	0.00207	0.0104	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Vismodegib—skin cancer	0.002	0.0101	CcSEcCtD
Pralatrexate—Abdominal pain—Vismodegib—skin cancer	0.00193	0.00972	CcSEcCtD
Pralatrexate—Back pain—Vemurafenib—skin cancer	0.00179	0.009	CcSEcCtD
Pralatrexate—Asthenia—Vismodegib—skin cancer	0.00175	0.00882	CcSEcCtD
Pralatrexate—Sepsis—Fluorouracil—skin cancer	0.00173	0.0087	CcSEcCtD
Pralatrexate—Pruritus—Vismodegib—skin cancer	0.00173	0.0087	CcSEcCtD
Pralatrexate—Diarrhoea—Vismodegib—skin cancer	0.00167	0.00841	CcSEcCtD
Pralatrexate—DHFR—E2F transcription factor network—XRCC1—skin cancer	0.00166	0.0303	CbGpPWpGaD
Pralatrexate—Cough—Vemurafenib—skin cancer	0.00161	0.00812	CcSEcCtD
Pralatrexate—Liver function test abnormal—Dactinomycin—skin cancer	0.0016	0.00806	CcSEcCtD
Pralatrexate—Toxic epidermal necrolysis—Dactinomycin—skin cancer	0.00156	0.00786	CcSEcCtD
Pralatrexate—Vomiting—Vismodegib—skin cancer	0.00155	0.00782	CcSEcCtD
Pralatrexate—Rash—Vismodegib—skin cancer	0.00154	0.00775	CcSEcCtD
Pralatrexate—Dermatitis—Vismodegib—skin cancer	0.00154	0.00774	CcSEcCtD
Pralatrexate—Pancytopenia—Bleomycin—skin cancer	0.00153	0.00768	CcSEcCtD
Pralatrexate—Back pain—Imiquimod—skin cancer	0.00152	0.00768	CcSEcCtD
Pralatrexate—DHFR—Fluoropyrimidine Activity—ERCC2—skin cancer	0.00152	0.0277	CbGpPWpGaD
Pralatrexate—TYMS—lymph node—skin cancer	0.00148	0.0156	CbGeAlD
Pralatrexate—DHFR—lymph node—skin cancer	0.00146	0.0155	CbGeAlD
Pralatrexate—Dehydration—Temozolomide—skin cancer	0.00146	0.00734	CcSEcCtD
Pralatrexate—Nausea—Vismodegib—skin cancer	0.00145	0.0073	CcSEcCtD
Pralatrexate—TYMS—E2F transcription factor network—XRCC1—skin cancer	0.00145	0.0264	CbGpPWpGaD
Pralatrexate—Hypokalaemia—Temozolomide—skin cancer	0.00143	0.00719	CcSEcCtD
Pralatrexate—Pancytopenia—Dactinomycin—skin cancer	0.00142	0.00717	CcSEcCtD
Pralatrexate—Toxic epidermal necrolysis—Temozolomide—skin cancer	0.00141	0.00711	CcSEcCtD
Pralatrexate—Neutropenia—Dactinomycin—skin cancer	0.0014	0.00706	CcSEcCtD
Pralatrexate—Cough—Imiquimod—skin cancer	0.00137	0.00692	CcSEcCtD
Pralatrexate—TYMS—Fluoropyrimidine Activity—ERCC2—skin cancer	0.00132	0.0242	CbGpPWpGaD
Pralatrexate—Decreased appetite—Vemurafenib—skin cancer	0.00131	0.0066	CcSEcCtD
Pralatrexate—Fatigue—Vemurafenib—skin cancer	0.0013	0.00655	CcSEcCtD
Pralatrexate—FPGS—Fluoropyrimidine Activity—TP53—skin cancer	0.0013	0.0237	CbGpPWpGaD
Pralatrexate—Constipation—Vemurafenib—skin cancer	0.00129	0.00649	CcSEcCtD
Pralatrexate—Pancytopenia—Temozolomide—skin cancer	0.00129	0.00648	CcSEcCtD
Pralatrexate—Oedema—Imiquimod—skin cancer	0.00129	0.00648	CcSEcCtD
Pralatrexate—Neutropenia—Temozolomide—skin cancer	0.00127	0.00638	CcSEcCtD
Pralatrexate—Upper respiratory tract infection—Temozolomide—skin cancer	0.00126	0.00634	CcSEcCtD
Pralatrexate—Tachycardia—Imiquimod—skin cancer	0.00125	0.00632	CcSEcCtD
Pralatrexate—Sepsis—Docetaxel—skin cancer	0.00125	0.00628	CcSEcCtD
Pralatrexate—Anorexia—Imiquimod—skin cancer	0.00123	0.00617	CcSEcCtD
Pralatrexate—Body temperature increased—Vemurafenib—skin cancer	0.00119	0.006	CcSEcCtD
Pralatrexate—Pancytopenia—Fluorouracil—skin cancer	0.00119	0.00597	CcSEcCtD
Pralatrexate—SLC19A1—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—skin cancer	0.00118	0.0215	CbGpPWpGaD
Pralatrexate—Upper respiratory tract infection—Fluorouracil—skin cancer	0.00116	0.00584	CcSEcCtD
Pralatrexate—Dyspnoea—Imiquimod—skin cancer	0.00115	0.00577	CcSEcCtD
Pralatrexate—Decreased appetite—Imiquimod—skin cancer	0.00112	0.00563	CcSEcCtD
Pralatrexate—Fatigue—Imiquimod—skin cancer	0.00111	0.00558	CcSEcCtD
Pralatrexate—Asthenia—Vemurafenib—skin cancer	0.00108	0.00545	CcSEcCtD
Pralatrexate—Pruritus—Vemurafenib—skin cancer	0.00107	0.00537	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Imiquimod—skin cancer	0.00105	0.0053	CcSEcCtD
Pralatrexate—Epistaxis—Fluorouracil—skin cancer	0.00105	0.00529	CcSEcCtD
Pralatrexate—Pain in extremity—Docetaxel—skin cancer	0.00104	0.00525	CcSEcCtD
Pralatrexate—Anaemia—Bleomycin—skin cancer	0.00103	0.00521	CcSEcCtD
Pralatrexate—Diarrhoea—Vemurafenib—skin cancer	0.00103	0.0052	CcSEcCtD
Pralatrexate—Body temperature increased—Imiquimod—skin cancer	0.00102	0.00512	CcSEcCtD
Pralatrexate—Abdominal pain—Imiquimod—skin cancer	0.00102	0.00512	CcSEcCtD
Pralatrexate—FPGS—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—skin cancer	0.001	0.0183	CbGpPWpGaD
Pralatrexate—Leukopenia—Bleomycin—skin cancer	0.001	0.00505	CcSEcCtD
Pralatrexate—Cough—Bleomycin—skin cancer	0.000976	0.00492	CcSEcCtD
Pralatrexate—Dehydration—Docetaxel—skin cancer	0.000969	0.00488	CcSEcCtD
Pralatrexate—Anaemia—Dactinomycin—skin cancer	0.000965	0.00486	CcSEcCtD
Pralatrexate—Liver function test abnormal—Docetaxel—skin cancer	0.000962	0.00485	CcSEcCtD
Pralatrexate—Vomiting—Vemurafenib—skin cancer	0.000958	0.00483	CcSEcCtD
Pralatrexate—Rash—Vemurafenib—skin cancer	0.00095	0.00479	CcSEcCtD
Pralatrexate—Dermatitis—Vemurafenib—skin cancer	0.00095	0.00478	CcSEcCtD
Pralatrexate—Toxic epidermal necrolysis—Docetaxel—skin cancer	0.000939	0.00473	CcSEcCtD
Pralatrexate—Leukopenia—Dactinomycin—skin cancer	0.000934	0.00471	CcSEcCtD
Pralatrexate—TYMS—Circadian rythm related genes—NKX2-1—skin cancer	0.000929	0.017	CbGpPWpGaD
Pralatrexate—Asthenia—Imiquimod—skin cancer	0.000922	0.00465	CcSEcCtD
Pralatrexate—Oedema—Bleomycin—skin cancer	0.000913	0.0046	CcSEcCtD
Pralatrexate—Back pain—Temozolomide—skin cancer	0.000913	0.0046	CcSEcCtD
Pralatrexate—Pruritus—Imiquimod—skin cancer	0.00091	0.00458	CcSEcCtD
Pralatrexate—Nausea—Vemurafenib—skin cancer	0.000895	0.00451	CcSEcCtD
Pralatrexate—Thrombocytopenia—Bleomycin—skin cancer	0.000894	0.0045	CcSEcCtD
Pralatrexate—Diarrhoea—Imiquimod—skin cancer	0.00088	0.00443	CcSEcCtD
Pralatrexate—SLC19A1—Folate Metabolism—TP53—skin cancer	0.000876	0.016	CbGpPWpGaD
Pralatrexate—Anaemia—Temozolomide—skin cancer	0.000872	0.0044	CcSEcCtD
Pralatrexate—Anorexia—Bleomycin—skin cancer	0.000871	0.00439	CcSEcCtD
Pralatrexate—Pancytopenia—Docetaxel—skin cancer	0.000856	0.00431	CcSEcCtD
Pralatrexate—Oedema—Dactinomycin—skin cancer	0.000852	0.00429	CcSEcCtD
Pralatrexate—Leukopenia—Temozolomide—skin cancer	0.000845	0.00426	CcSEcCtD
Pralatrexate—Neutropenia—Docetaxel—skin cancer	0.000842	0.00424	CcSEcCtD
Pralatrexate—Thrombocytopenia—Dactinomycin—skin cancer	0.000834	0.0042	CcSEcCtD
Pralatrexate—Cough—Temozolomide—skin cancer	0.000824	0.00415	CcSEcCtD
Pralatrexate—Vomiting—Imiquimod—skin cancer	0.000817	0.00412	CcSEcCtD
Pralatrexate—Dyspnoea—Bleomycin—skin cancer	0.000814	0.0041	CcSEcCtD
Pralatrexate—Anorexia—Dactinomycin—skin cancer	0.000812	0.00409	CcSEcCtD
Pralatrexate—Rash—Imiquimod—skin cancer	0.000811	0.00408	CcSEcCtD
Pralatrexate—Dermatitis—Imiquimod—skin cancer	0.00081	0.00408	CcSEcCtD
Pralatrexate—Anaemia—Fluorouracil—skin cancer	0.000804	0.00405	CcSEcCtD
Pralatrexate—SLC19A1—Folate Metabolism—IL6—skin cancer	0.000802	0.0146	CbGpPWpGaD
Pralatrexate—Decreased appetite—Bleomycin—skin cancer	0.000794	0.004	CcSEcCtD
Pralatrexate—Leukopenia—Fluorouracil—skin cancer	0.000779	0.00392	CcSEcCtD
Pralatrexate—Oedema—Temozolomide—skin cancer	0.00077	0.00388	CcSEcCtD
Pralatrexate—Nausea—Imiquimod—skin cancer	0.000764	0.00385	CcSEcCtD
Pralatrexate—Epistaxis—Docetaxel—skin cancer	0.000758	0.00382	CcSEcCtD
Pralatrexate—Thrombocytopenia—Temozolomide—skin cancer	0.000754	0.0038	CcSEcCtD
Pralatrexate—Decreased appetite—Dactinomycin—skin cancer	0.00074	0.00373	CcSEcCtD
Pralatrexate—Fatigue—Dactinomycin—skin cancer	0.000734	0.0037	CcSEcCtD
Pralatrexate—Anorexia—Temozolomide—skin cancer	0.000734	0.0037	CcSEcCtD
Pralatrexate—Body temperature increased—Bleomycin—skin cancer	0.000722	0.00364	CcSEcCtD
Pralatrexate—Oedema—Fluorouracil—skin cancer	0.00071	0.00358	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Dactinomycin—skin cancer	0.000697	0.00351	CcSEcCtD
Pralatrexate—Thrombocytopenia—Fluorouracil—skin cancer	0.000695	0.0035	CcSEcCtD
Pralatrexate—Tachycardia—Fluorouracil—skin cancer	0.000693	0.00349	CcSEcCtD
Pralatrexate—Dyspnoea—Temozolomide—skin cancer	0.000687	0.00346	CcSEcCtD
Pralatrexate—Anorexia—Fluorouracil—skin cancer	0.000677	0.00341	CcSEcCtD
Pralatrexate—Abdominal pain—Dactinomycin—skin cancer	0.000673	0.00339	CcSEcCtD
Pralatrexate—Body temperature increased—Dactinomycin—skin cancer	0.000673	0.00339	CcSEcCtD
Pralatrexate—Decreased appetite—Temozolomide—skin cancer	0.00067	0.00337	CcSEcCtD
Pralatrexate—Fatigue—Temozolomide—skin cancer	0.000664	0.00335	CcSEcCtD
Pralatrexate—Constipation—Temozolomide—skin cancer	0.000659	0.00332	CcSEcCtD
Pralatrexate—Asthenia—Bleomycin—skin cancer	0.000655	0.0033	CcSEcCtD
Pralatrexate—Pruritus—Bleomycin—skin cancer	0.000646	0.00326	CcSEcCtD
Pralatrexate—Dyspnoea—Fluorouracil—skin cancer	0.000633	0.00319	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Temozolomide—skin cancer	0.00063	0.00317	CcSEcCtD
Pralatrexate—Decreased appetite—Fluorouracil—skin cancer	0.000617	0.00311	CcSEcCtD
Pralatrexate—SLC19A1—Metabolism—PLIN2—skin cancer	0.000613	0.0112	CbGpPWpGaD
Pralatrexate—Asthenia—Dactinomycin—skin cancer	0.000611	0.00308	CcSEcCtD
Pralatrexate—Body temperature increased—Temozolomide—skin cancer	0.000609	0.00307	CcSEcCtD
Pralatrexate—Abdominal pain—Temozolomide—skin cancer	0.000609	0.00307	CcSEcCtD
Pralatrexate—Back pain—Docetaxel—skin cancer	0.000607	0.00306	CcSEcCtD
Pralatrexate—SLC19A1—Disease—CSPG4—skin cancer	0.00059	0.0108	CbGpPWpGaD
Pralatrexate—DHFR—Retinoblastoma (RB) in Cancer—CDK4—skin cancer	0.000586	0.0107	CbGpPWpGaD
Pralatrexate—Diarrhoea—Dactinomycin—skin cancer	0.000583	0.00294	CcSEcCtD
Pralatrexate—Vomiting—Bleomycin—skin cancer	0.000581	0.00293	CcSEcCtD
Pralatrexate—Anaemia—Docetaxel—skin cancer	0.00058	0.00292	CcSEcCtD
Pralatrexate—Rash—Bleomycin—skin cancer	0.000576	0.0029	CcSEcCtD
Pralatrexate—Dermatitis—Bleomycin—skin cancer	0.000575	0.0029	CcSEcCtD
Pralatrexate—Leukopenia—Docetaxel—skin cancer	0.000562	0.00283	CcSEcCtD
Pralatrexate—Body temperature increased—Fluorouracil—skin cancer	0.000561	0.00283	CcSEcCtD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—SHH—skin cancer	0.00056	0.0102	CbGpPWpGaD
Pralatrexate—Asthenia—Temozolomide—skin cancer	0.000553	0.00278	CcSEcCtD
Pralatrexate—Cough—Docetaxel—skin cancer	0.000548	0.00276	CcSEcCtD
Pralatrexate—Pruritus—Temozolomide—skin cancer	0.000545	0.00275	CcSEcCtD
Pralatrexate—Nausea—Bleomycin—skin cancer	0.000542	0.00273	CcSEcCtD
Pralatrexate—Vomiting—Dactinomycin—skin cancer	0.000542	0.00273	CcSEcCtD
Pralatrexate—DHFR—Fluoropyrimidine Activity—TP53—skin cancer	0.000542	0.00989	CbGpPWpGaD
Pralatrexate—Rash—Dactinomycin—skin cancer	0.000537	0.00271	CcSEcCtD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—SMO—skin cancer	0.00053	0.00968	CbGpPWpGaD
Pralatrexate—Diarrhoea—Temozolomide—skin cancer	0.000527	0.00266	CcSEcCtD
Pralatrexate—FPGS—Metabolism—PLIN2—skin cancer	0.000521	0.00951	CbGpPWpGaD
Pralatrexate—DHFR—E2F transcription factor network—CDKN2A—skin cancer	0.000516	0.00941	CbGpPWpGaD
Pralatrexate—Oedema—Docetaxel—skin cancer	0.000512	0.00258	CcSEcCtD
Pralatrexate—TYMS—Retinoblastoma (RB) in Cancer—CDK4—skin cancer	0.000512	0.00934	CbGpPWpGaD
Pralatrexate—Nausea—Dactinomycin—skin cancer	0.000506	0.00255	CcSEcCtD
Pralatrexate—Pruritus—Fluorouracil—skin cancer	0.000502	0.00253	CcSEcCtD
Pralatrexate—Thrombocytopenia—Docetaxel—skin cancer	0.000502	0.00253	CcSEcCtD
Pralatrexate—FPGS—Disease—CSPG4—skin cancer	0.000501	0.00915	CbGpPWpGaD
Pralatrexate—Tachycardia—Docetaxel—skin cancer	0.0005	0.00252	CcSEcCtD
Pralatrexate—SLC19A1—Metabolism—CSPG4—skin cancer	0.000494	0.00902	CbGpPWpGaD
Pralatrexate—Vomiting—Temozolomide—skin cancer	0.00049	0.00247	CcSEcCtD
Pralatrexate—Anorexia—Docetaxel—skin cancer	0.000488	0.00246	CcSEcCtD
Pralatrexate—Rash—Temozolomide—skin cancer	0.000486	0.00245	CcSEcCtD
Pralatrexate—Diarrhoea—Fluorouracil—skin cancer	0.000486	0.00245	CcSEcCtD
Pralatrexate—Dermatitis—Temozolomide—skin cancer	0.000485	0.00244	CcSEcCtD
Pralatrexate—TYMS—Fluoropyrimidine Activity—TP53—skin cancer	0.000473	0.00863	CbGpPWpGaD
Pralatrexate—Nausea—Temozolomide—skin cancer	0.000458	0.00231	CcSEcCtD
Pralatrexate—Dyspnoea—Docetaxel—skin cancer	0.000457	0.0023	CcSEcCtD
Pralatrexate—Vomiting—Fluorouracil—skin cancer	0.000451	0.00227	CcSEcCtD
Pralatrexate—TYMS—E2F transcription factor network—CDKN2A—skin cancer	0.00045	0.00821	CbGpPWpGaD
Pralatrexate—Rash—Fluorouracil—skin cancer	0.000448	0.00225	CcSEcCtD
Pralatrexate—Dermatitis—Fluorouracil—skin cancer	0.000447	0.00225	CcSEcCtD
Pralatrexate—Decreased appetite—Docetaxel—skin cancer	0.000445	0.00224	CcSEcCtD
Pralatrexate—Fatigue—Docetaxel—skin cancer	0.000442	0.00223	CcSEcCtD
Pralatrexate—Constipation—Docetaxel—skin cancer	0.000438	0.00221	CcSEcCtD
Pralatrexate—Nausea—Fluorouracil—skin cancer	0.000422	0.00212	CcSEcCtD
Pralatrexate—FPGS—Metabolism—CSPG4—skin cancer	0.00042	0.00767	CbGpPWpGaD
Pralatrexate—DHFR—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—skin cancer	0.000419	0.00765	CbGpPWpGaD
Pralatrexate—Gastrointestinal pain—Docetaxel—skin cancer	0.000419	0.00211	CcSEcCtD
Pralatrexate—DHFR—Mitotic G1-G1/S phases—CDK4—skin cancer	0.000412	0.00753	CbGpPWpGaD
Pralatrexate—Abdominal pain—Docetaxel—skin cancer	0.000405	0.00204	CcSEcCtD
Pralatrexate—Body temperature increased—Docetaxel—skin cancer	0.000405	0.00204	CcSEcCtD
Pralatrexate—SLC19A1—Disease—SHH—skin cancer	0.000401	0.00732	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—ENO2—skin cancer	0.000401	0.00732	CbGpPWpGaD
Pralatrexate—Asthenia—Docetaxel—skin cancer	0.000368	0.00185	CcSEcCtD
Pralatrexate—Pruritus—Docetaxel—skin cancer	0.000362	0.00183	CcSEcCtD
Pralatrexate—TYMS—Mitotic G1-G1/S phases—CDK4—skin cancer	0.00036	0.00657	CbGpPWpGaD
Pralatrexate—Diarrhoea—Docetaxel—skin cancer	0.000351	0.00177	CcSEcCtD
Pralatrexate—FPGS—Disease—ENO2—skin cancer	0.000341	0.00622	CbGpPWpGaD
Pralatrexate—FPGS—Disease—SHH—skin cancer	0.000341	0.00622	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—ENO2—skin cancer	0.000336	0.00613	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—FOXO4—skin cancer	0.000327	0.00597	CbGpPWpGaD
Pralatrexate—Vomiting—Docetaxel—skin cancer	0.000326	0.00164	CcSEcCtD
Pralatrexate—Rash—Docetaxel—skin cancer	0.000323	0.00163	CcSEcCtD
Pralatrexate—Dermatitis—Docetaxel—skin cancer	0.000323	0.00163	CcSEcCtD
Pralatrexate—DHFR—Mitotic G1-G1/S phases—CDKN2A—skin cancer	0.000315	0.00576	CbGpPWpGaD
Pralatrexate—DHFR—Folate Metabolism—TP53—skin cancer	0.000311	0.00568	CbGpPWpGaD
Pralatrexate—Nausea—Docetaxel—skin cancer	0.000304	0.00153	CcSEcCtD
Pralatrexate—FPGS—Metabolism—ENO2—skin cancer	0.000285	0.00521	CbGpPWpGaD
Pralatrexate—DHFR—Folate Metabolism—IL6—skin cancer	0.000285	0.0052	CbGpPWpGaD
Pralatrexate—FPGS—Disease—FOXO4—skin cancer	0.000278	0.00507	CbGpPWpGaD
Pralatrexate—TYMS—Mitotic G1-G1/S phases—CDKN2A—skin cancer	0.000275	0.00502	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	0.000273	0.00498	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—MLH1—skin cancer	0.000266	0.00486	CbGpPWpGaD
Pralatrexate—TYMS—Circadian rythm related genes—CDK4—skin cancer	0.000262	0.00478	CbGpPWpGaD
Pralatrexate—DHFR—Retinoblastoma (RB) in Cancer—TP53—skin cancer	0.000249	0.00455	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—ERCC2—skin cancer	0.000233	0.00425	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—MLH1—skin cancer	0.000232	0.00424	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—TERT—skin cancer	0.000218	0.00398	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—PLIN2—skin cancer	0.000218	0.00397	CbGpPWpGaD
Pralatrexate—TYMS—Retinoblastoma (RB) in Cancer—TP53—skin cancer	0.000218	0.00397	CbGpPWpGaD
Pralatrexate—DHFR—Disease—CSPG4—skin cancer	0.000209	0.00382	CbGpPWpGaD
Pralatrexate—FPGS—Disease—ERCC2—skin cancer	0.000198	0.00361	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—ERCC2—skin cancer	0.000195	0.00356	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	0.000195	0.00356	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—PLIN2—skin cancer	0.00019	0.00347	CbGpPWpGaD
Pralatrexate—FPGS—Disease—TERT—skin cancer	0.000186	0.00339	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—CSPG4—skin cancer	0.000175	0.0032	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—BRAF—skin cancer	0.000173	0.00316	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—ERCC2—skin cancer	0.000166	0.00303	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—CSPG4—skin cancer	0.000153	0.00279	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—CDK4—skin cancer	0.000151	0.00276	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—TERT—skin cancer	0.000151	0.00276	CbGpPWpGaD
Pralatrexate—FPGS—Disease—BRAF—skin cancer	0.000147	0.00268	CbGpPWpGaD
Pralatrexate—DHFR—Disease—ENO2—skin cancer	0.000142	0.0026	CbGpPWpGaD
Pralatrexate—DHFR—Disease—SHH—skin cancer	0.000142	0.0026	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—PTGS2—skin cancer	0.00014	0.00255	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—CDK4—skin cancer	0.000135	0.00247	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—CDK4—skin cancer	0.000132	0.00241	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—TERT—skin cancer	0.000132	0.00241	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	0.000131	0.00238	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—ENO2—skin cancer	0.000119	0.00218	CbGpPWpGaD
Pralatrexate—FPGS—Disease—PTGS2—skin cancer	0.000119	0.00217	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—CDK4—skin cancer	0.000118	0.00215	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—PTGS2—skin cancer	0.000117	0.00213	CbGpPWpGaD
Pralatrexate—DHFR—Disease—FOXO4—skin cancer	0.000116	0.00212	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	0.000116	0.00212	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—CDKN2A—skin cancer	0.000116	0.00211	CbGpPWpGaD
Pralatrexate—TYMS—Circadian rythm related genes—TP53—skin cancer	0.000111	0.00203	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—NRAS—skin cancer	0.000109	0.00198	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—ENO2—skin cancer	0.000104	0.0019	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—CDKN2A—skin cancer	0.000103	0.00189	CbGpPWpGaD
Pralatrexate—TYMS—Circadian rythm related genes—IL6—skin cancer	0.000102	0.00186	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—CDKN2A—skin cancer	0.000101	0.00184	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—PTGS2—skin cancer	9.94e-05	0.00182	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—KRAS—skin cancer	9.35e-05	0.00171	CbGpPWpGaD
Pralatrexate—FPGS—Disease—NRAS—skin cancer	9.24e-05	0.00169	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—CDKN2A—skin cancer	9.02e-05	0.00165	CbGpPWpGaD
Pralatrexate—DHFR—Disease—ERCC2—skin cancer	8.27e-05	0.00151	CbGpPWpGaD
Pralatrexate—FPGS—Disease—KRAS—skin cancer	7.95e-05	0.00145	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—HRAS—skin cancer	7.95e-05	0.00145	CbGpPWpGaD
Pralatrexate—DHFR—Disease—TERT—skin cancer	7.75e-05	0.00142	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—IL6—skin cancer	7.61e-05	0.00139	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—ERCC2—skin cancer	6.93e-05	0.00126	CbGpPWpGaD
Pralatrexate—FPGS—Disease—HRAS—skin cancer	6.76e-05	0.00123	CbGpPWpGaD
Pralatrexate—FPGS—Disease—IL6—skin cancer	6.47e-05	0.00118	CbGpPWpGaD
Pralatrexate—DHFR—Disease—BRAF—skin cancer	6.14e-05	0.00112	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—ERCC2—skin cancer	6.04e-05	0.0011	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—TP53—skin cancer	5.75e-05	0.00105	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—TP53—skin cancer	5.02e-05	0.000917	CbGpPWpGaD
Pralatrexate—DHFR—Disease—PTGS2—skin cancer	4.96e-05	0.000905	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—PTGS2—skin cancer	4.15e-05	0.000758	CbGpPWpGaD
Pralatrexate—DHFR—Disease—NRAS—skin cancer	3.86e-05	0.000704	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—PTGS2—skin cancer	3.62e-05	0.000662	CbGpPWpGaD
Pralatrexate—DHFR—Disease—KRAS—skin cancer	3.32e-05	0.000606	CbGpPWpGaD
Pralatrexate—DHFR—Disease—HRAS—skin cancer	2.82e-05	0.000515	CbGpPWpGaD
Pralatrexate—DHFR—Disease—IL6—skin cancer	2.7e-05	0.000493	CbGpPWpGaD
